Editorial review of biologic pharmacokinetics and CNS delivery
Donanemab illustrates both the opportunity and the delivery challenge of antibody therapeutics for central nervous system disorders.
FDA approval of Kisunla™ (donanemab-azbt) in 2024 for early symptomatic Alzheimer’s disease marked an important step for amyloid-targeting therapies. More broadly, it provides a useful clinical context for examining how biologics are characterized, delivered and translated for diseases of the central nervous system (CNS), where the blood–brain barrier (BBB) remains a central development challenge.
Donanemab-azbt is a monoclonal antibody directed against a modified form of beta-amyloid found in amyloid plaques. By binding plaque-associated amyloid, the therapy is intended to support plaque clearance and slow clinical decline in appropriately selected patients with early symptomatic Alzheimer’s disease.
The product’s clinical relevance does not remove the fundamental delivery constraints faced by large molecules in the CNS. Antibodies generally distribute differently from small molecules, and therapeutic development must account for limited brain exposure, systemic clearance, immunogenicity, target biology and safety monitoring.
Important distinction. Receptor-mediated transcytosis and PEGylation are general strategies explored across CNS-biologic research. They should not be presented as established delivery features of Kisunla unless directly supported by product-specific evidence. FDA labeling describes Kisunla as an intravenously administered monoclonal antibody with pharmacokinetics consistent with IgG proteolytic elimination.
Pharmacokinetics determines how a therapeutic is absorbed, distributed, cleared and maintained at a biologically relevant exposure. For CNS-directed biologics, the central question is not simply whether a molecule reaches systemic circulation, but whether sufficient exposure can be achieved at the intended brain target while maintaining an acceptable safety margin.
The FDA prescribing information for Kisunla reports population pharmacokinetic characterization in patients with Alzheimer’s disease. The label describes a central volume of distribution of 3.36 L, a mean terminal half-life of approximately 12.1 days and degradation by proteolytic enzymes in a manner expected for endogenous IgG. Anti-drug antibodies may increase clearance, illustrating how immunogenicity can influence exposure for biologic therapies.
The regulatory and development lesson is clear: CNS biologic programs require integrated assessment of systemic exposure, target engagement, biodistribution, pharmacodynamics and safety rather than reliance on a single PK parameter.
The CNS contains multiple interfaces that regulate movement of substances from blood to brain, including the BBB, blood–cerebrospinal-fluid barrier and arachnoid barrier. Together, these structures control entry of both small and large molecules.
BBB structure. Tight endothelial junctions, astrocyte end-feet and pericytes form a highly selective interface. This architecture limits paracellular movement of hydrophilic molecules and restricts transcellular diffusion according to a molecule’s physicochemical properties.
Large-molecule challenge. Antibodies and other biologics generally enter the brain at low rates relative to their circulating concentration. Molecular size, charge, glycosylation, Fc receptor interactions, target-mediated disposition and clearance pathways can all influence tissue distribution and persistence.
A rigorous CNS-delivery strategy combines complementary in vitro and in vivo systems. No single model fully predicts human brain exposure, so decision-making benefits from a connected evidence package that tests transport, distribution, target engagement and functional consequences.
Human-derived and engineered cell models can help assess transport properties and support early screening of biologic candidates across BBB-relevant barriers.
Overexpression models: MDCK, Caco-2, MDCK-MDR1 and MDCK-BCRP.
Single-culture models: bEnd.3 and hCMEC/D3.
Co-culture models: Astrocyte, bEnd.3 and hCMEC/D3 co-culture systems.
Intravenous dosing, brain perfusion, microdialysis, quantitative whole-body autoradiography, molecular imaging methods such as SPECT and PET, and tissue bioanalysis can be combined to assess BBB penetration and CNS distribution in animal models.
Multiple strategies are being explored to improve brain exposure of biologics. Their applicability depends on the modality, receptor biology, target location, desired exposure profile and safety constraints of each program.
The approval of amyloid-targeting antibodies has expanded the treatment landscape for Alzheimer’s disease and underscored the potential of biologics for CNS disorders. At the same time, successful translation requires careful management of exposure, patient selection, dose scheduling, pharmacodynamic response and mechanism-related safety risks.
Safety monitoring matters. The FDA prescribing information for Kisunla includes warnings for amyloid-related imaging abnormalities, including ARIA with edema and hemosiderin deposition. This reinforces the importance of integrating PK, biomarker and safety data throughout CNS-biologic development.
For discovery teams, the practical objective is to build a decision-enabling cascade that links BBB transport evidence with exposure–response relationships, target engagement, functional biology and translational biomarkers.
Donanemab-azbt demonstrates the clinical relevance of antibody therapeutics in Alzheimer’s disease, while also highlighting the need for disciplined pharmacokinetic and translational thinking in CNS drug discovery.
Future progress will depend on improved delivery technologies, predictive human-relevant models, well-chosen biomarkers and careful balancing of target exposure with safety. Understanding what a clinical product specifically demonstrates—and what remains a broader research hypothesis—is essential for advancing the next generation of CNS biologics.
KISUNLA (donanemab-azbt) Prescribing Information, U.S. Food and Drug Administration ↗
Kouhi A, Pachipulusu V, Kapenstein T, et al. Brain disposition of antibody-based therapeutics: dogma, approaches and perspectives. International Journal of Molecular Sciences. 2021;22(12):6442.
Xia CY, Wang ZZ, Yamakuni T, et al. A novel mechanism of depression: role for connexins. European Neuropsychopharmacology. 2018;28(4):483-498.
Jafari B, Pourseif MM, Barar J, et al. Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opinion on Drug Delivery. 2019;16(6):583-605.
Zhao L, Ren T, Wang DD. Clinical pharmacology considerations in biologics development. Acta Pharmacologica Sinica. 2012;33(11):1339-1347.
Cavaco M, Gaspar D, ARB Castanho M, et al. Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? Pharmaceutics. 2020;12(1):62.
Ho RJY. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs. John Wiley & Sons. 2013.
Rondon A, Mahri S, Morales-Yanez F, et al. Protein engineering strategies for improved pharmacokinetics. Advanced Functional Materials. 2021;31(44):2101633.
Gueorguieva I, Willis BA, Chua L, et al. Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer’s disease. Clinical Pharmacology & Therapeutics. 2023.
Donanemab | ALZFORUM. Available at: https://www.alzforum.org/therapeutics/donanemab.
2026-07-29
2024-11-01
2024-07-17
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
